NCT06561048 - Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

July 31, 2028

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeSystemic Anaplastic Large Cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, T-Cell

Interventions

DRUG

Soquelitinib

Soquelitinib 200 mg tablets will be taken by mouth two times a day

DRUG

Belinostat

Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle

DRUG

Pralatrexate

Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle

Trial Locations (1)

94080

RECRUITING

Corvus Pharmaceuticals, South San Francisco